Sam Brusco, Associate Editor03.25.24
Abbott has earned CE mark approval for its Assert-IQ insertable cardiac monitor (ICM) for diagnostic evaluation and long-term monitoring of people experiencing abnormal heartbeats.
The Assert-IQ ICM is inserted in a minimally invasive procedure under the skin of the chest to monitor the heart continuously and detect arrhythmias. It’s connected to a transmitter by Bluetooth to check heart rhythms every 20 seconds, sending findings in real-time to their clinic’s portal.
According to Abbott, Assert-IQ has the longest battery life for a Bluetooth-enabled ICM. It has two options: one for a battery life of at least three years and another for at least six years. The three-year option might be chosen for more traditional monitoring like diagnosing fainting or heart palpitations, or detecting abnormal heart rhythms. The six-year option is meant for longer-term monitoring, for those at risk of developing arrhythmias.
"As the prevalence of abnormal heart rhythms rise, physicians increasingly rely on ICM technology to diagnosis various heart conditions," said Leonard Ganz, M.D., divisional vice president of medical affairs and chief medical officer of Abbott's cardiac rhythm management business. "Introducing Assert-IQ in Europe will expand access to transformative benefits of long-term monitoring and more clinically relevant information, and allow care providers to make clinical decisions faster and with more precision."
"Assert-IQ is the next generation of implantable cardiac monitors, providing physicians with actionable data and new patient insights," added Professor Paolo Della Bella, MD, head of the arrhythmia department at IRCCS San Raffaele Scientific Institute in Italy. "The real-time data, advanced algorithms and diagnostic accuracy empower physicians to deliver more personalized and effective care. For those with abnormal heart rhythms, Assert-IQ ICM provides peace of mind and the freedom to live their lives with confidence."
The Assert-IQ ICM is inserted in a minimally invasive procedure under the skin of the chest to monitor the heart continuously and detect arrhythmias. It’s connected to a transmitter by Bluetooth to check heart rhythms every 20 seconds, sending findings in real-time to their clinic’s portal.
According to Abbott, Assert-IQ has the longest battery life for a Bluetooth-enabled ICM. It has two options: one for a battery life of at least three years and another for at least six years. The three-year option might be chosen for more traditional monitoring like diagnosing fainting or heart palpitations, or detecting abnormal heart rhythms. The six-year option is meant for longer-term monitoring, for those at risk of developing arrhythmias.
"As the prevalence of abnormal heart rhythms rise, physicians increasingly rely on ICM technology to diagnosis various heart conditions," said Leonard Ganz, M.D., divisional vice president of medical affairs and chief medical officer of Abbott's cardiac rhythm management business. "Introducing Assert-IQ in Europe will expand access to transformative benefits of long-term monitoring and more clinically relevant information, and allow care providers to make clinical decisions faster and with more precision."
"Assert-IQ is the next generation of implantable cardiac monitors, providing physicians with actionable data and new patient insights," added Professor Paolo Della Bella, MD, head of the arrhythmia department at IRCCS San Raffaele Scientific Institute in Italy. "The real-time data, advanced algorithms and diagnostic accuracy empower physicians to deliver more personalized and effective care. For those with abnormal heart rhythms, Assert-IQ ICM provides peace of mind and the freedom to live their lives with confidence."